Calyxt, Inc. Common Stock Offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 4,057,500 shares of common stock of Calyxt, Inc., including 457,500…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Davis Polk Advises Shire on Its Proposed Acquisition by Takeda
Davis Polk, together with Slaughter and May, is advising Shire plc in connection with a recommended cash and stock offer for Shire’s entire share capital by Takeda Pharmaceutical Company…
ASLAN Pharmaceuticals Initial Public Offering and NASDAQ Listing
Davis Polk advised the joint book-running managers and representatives of the underwriters in the approximately $42.2 million initial public offering by ASLAN Pharmaceuticals Limited…
Unity Biotechnology, Inc. $85 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 5,000,000 shares of common stock of Unity Biotechnology, Inc. Unity…
Ping An Healthcare and Technology Company Limited HK$8.77 Billion ($1.12 Billion) Initial Public Offering
Davis Polk advised the joint global coordinators in the Hong Kong initial public offering of Ping An Healthcare and Technology Company Limited. The gross proceeds from the offering…
Davis Polk Advises Notre Dame Intermédica on Its R$2.4 Billion Initial Public Offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the initial public offering by Notre Dame Intermédica and by Bain Capital, the controlling shareholder of…
Aeglea BioTherapeutics $36 Million Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $36 million SEC-registered common stock offering by Aeglea BioTherapeutics, Inc. The common stock is listed on…
Cellectis S.A. Follow-On Offering
Davis Polk advised the representatives of the underwriters in connection with the $175 million public offering by Cellectis S.A. of 5,646,000 American Depositary Shares, each representing…
PTC Therapeutics, Inc. Common Stock Offering
Davis Polk advised the lead book-running managers and representatives of the underwriters in connection with the SEC-registered offering of 4,000,000 shares of common stock of PTC…
Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 5.500% senior notes…